User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate

Drug and Alcohol Dependence

Volumn 178, Issue , 2017, Pages 32-38

  Chan, Gary C K ^a   Hall, Wayne ^a   Freeman, Tom P ^b,c   Ferris, Jason ^a   Kelly, Adrian B ^a   Winstock, Adam ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Global Drug Survey   (United Kingdom)

Author keywords

Butane Hash Oil; Cannabis concentrate; Potency; Profile; THC; User characteristics

Indexed keywords

AMPHETAMINE; BUTANE HASH OIL; CANNABIS DERIVATIVE; COCAINE; DIAMORPHINE; DRONABINOL; ILLICIT DRUG; LYSERGIDE; METHAMPHETAMINE; MIDOMAFETAMINE; POTENCY HERBAL CANNABIS; UNCLASSIFIED DRUG; CANNABIS; OIL;

ADULT; ANXIETY; ARTICLE; CANNABIS USE; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG POTENCY; FEMALE; GLOBAL DRUG SURVEY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; ONLINE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SAMPLE SIZE; SELF REPORT; SOCIAL NETWORK; SUBSTANCE USE; CANNABIS ADDICTION; DRUG USE; PSYCHOLOGY; QUESTIONNAIRE; YOUNG ADULT;

ADULT; ANXIETY; CANNABIS; DEPRESSION; DRUG USERS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; OILS; PSYCHOTIC DISORDERS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85020776057     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2017.04.014     Document Type: Article

References (41)

1. AIHW, 2013 National Drug Strategy Household Survey Report. Drug Statistics Series No. 28., 2014, Australian Institute of Health and Welfare, Canberra.
2. Barratt, M.J., Ferris, J.A., Zahnow, R., Palamar, J.J., Maier, L.J., Winstock, A.R., 2017. Moving on from representativeness: Testing the utility of the Global Drug Survey. Substance Abuse: Research and Treatment. Accepted 31/05/2017.
3. Cavazos-Rehg, P.A., Sowles, S.J., Krauss, M.J., Agbonavbare, V., Grucza, R., Bierut, L., A content analysis of tweets about high-potency marijuana. Drug Alcohol Depend. 166 (2016), 100–108, 10.1016/j.drugalcdep.2016.06.034.
4. Crawford, A., Rise in UK Explosions Linked to Super-Strength Cannabis. 2016, BBC News Retrieved from http://www.bbc.com/news/uk-36988316.
5. Curran, H.V., Freeman, T.P., Mokrysz, C., Lewis, D.A., Morgan, C.J., Parsons, L.H., Keep off the grass? Cannabis, cognition and addiction. Nat. Rev. Neurosci. 17 (2016), 293–306, 10.1038/nrn.2016.28.
6. Daniulaityte, R., Nahhas, R.W., Wijeratne, S., Carlson, R.G., Lamy, F.R., Martins, S.S., Boyer, E.W., Smith, G.A., Sheth, A., Time for dabs: analyzing twitter data on marijuana concentrates across the U.S. Drug Alcohol Depend. 155 (2015), 307–311, 10.1016/j.drugalcdep.2015.07.1199.
7. De Hert, M., Correll, C.U., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I., Detraux, J., Gautam, S., Möller, H.J., Ndetei, D.M., Newcomer, J.W., Uwakwe, R., Leucht, S., Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10 (2011), 52–77.
8. Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., Stilo, S.A., Marques, T.R., Mondelli, V., Dazzan, P., Pariante, C., David, A.S., Gaughran, F., Atakan, Z., Iyegbe, C., Powell, J., Morgan, C., Lynskey, M., Murray, R.M., Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2 (2015), 233–238, 10.1016/s2215-0366(14)00117-5.
9. ElSohly, M.A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., Church, J.C., Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol. Psychiatry 79 (2016), 613–619, 10.1016/j.biopsych.2016.01.004.
10. Englund, A., Freeman, T.P., Murray, R.M., McGuire, P., Can we make cannabis safer?. Lancet Psychiatry, 2017, 30075-5 S2215-0366.
11. Freeman, T., Swift, W., Cannabis potency: the need for global monitoring. Addiction 111 (2016), 376–377.
12. Freeman, T.P., Winstock, A.R., Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol. Med. 45 (2015), 3181–3189, 10.1017/S0033291715001178.
13. Freeman, T.P., Morgan, C.J., Hindocha, C., Schafer, G., Das, R.K., Curran, H.V., Just say ‘know’: how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?. Addiction 109 (2014), 1686–1694.
14. Green, B., Kavanagh, D., Young, R., Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 22 (2003), 453–460, 10.1080/09595230310001613976.
15. Hall, W., Degenhardt, L., High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ, 350, 2015, h1205, 10.1136/bmj.h1205.
16. Hardwick, S., King, L.A., Home Office Cannabis Potency Study 2008. 2008, Home Office Scientific Development Branch, St. Albans.
17. Hindocha, C., Freeman, T.P., Ferris, J.A., Lynskey, M.T., Winstock, A.R., No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front. Psychiatry, 7, 2016, 104, 10.3389/fpsyt.2016.00104.
18. Iversen, L.L., The Science Of Marijuana. 2001, Oxford University Press.
19. Jensen, G., Bertelotti, R., Greenhalgh, D., Palmieri, T., Maguina, P., Honey oil burns: a growing problem. J. Burn Care Res. 36 (2015), e34–e37, 10.1097/bcr.0000000000000067.
20. Jensen, R.P., Luo, W., Pankow, J.F., Strongin, R.M., Peyton, D.H., Hidden formaldehyde in e-cigarette aerosols. N. Engl. J. Med. 372 (2015), 392–394, 10.1056/NEJMc1413069.
21. Loflin, M., Earleywine, M., A new method of cannabis ingestion: the dangers of dabs?. Addict. Behav. 39 (2014), 1430–1433, 10.1016/j.addbeh.2014.05.013.
22. Miller, B.L., Stogner, J.M., Miller, J.M., Exploring butane hash oil use: a research note. J. Psychoact. Drugs 48 (2016), 44–49, 10.1080/02791072.2015.1118173.
23. Morean, M.E., Kong, G., Camenga, D.R., Cavallo, D.A., Krishnan-Sarin, S., High school students’ use of electronic cigarettes to vaporize cannabis. Pediatrics 136 (2015), 611–616.
24. Niesink, R., Rigter, S., Koeter, M.W., Brunt, T.M., Potency trends of Delta9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15. Addiction 110 (2015), 1941–1950, 10.1111/add.13082.
25. Pijlman, F., Rigter, S., Hoek, J., Goldschmidt, H., Niesink, R., Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict. Biol. 10 (2005), 171–180.
26. Potter, G.R., Chatwin, C., The problem with skunk. Drugs Alcohol Today 12 (2012), 232–240, 10.1108/17459261211286645.
27. Raber, J.C., Elzinga, S., Kaplan, C., Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J. Toxicol. Sci. 40 (2015), 797–803, 10.2131/jts.40.797.
28. Rotermann, M., Langlois, K., Prevalence and correlates of marijuana use in Canada, 2012. Health Rep. 26 (2015), 10–15.
29. Rubin, D.B., Multiple Imputation for Nonresponse in Surveys. 2009, John Wiley and Sons., New York, NY.
30. Russo, E.B., Current therapeutic cannabis controversies and clinical trial design issues. Front. Pharmacol., 7, 2016, 309, 10.3389/fphar.2016.00309.
31. SAMHSA, U.S. National Survey on Drug Use and Health: Model-Based Prevalence Estimates (50 States and the District of Columbia) 2013–2014. 2014, Substance Abuse and Mental Health Services Adminstration, Rockville, MD.
32. StataCorp, Stata Statistical Software: Release 13. 2013, StataCorp LP., College Station, TX.
33. Stogner, J.M., Miller, B.L., Assessing the dangers of dabbing: mere marijuana or harmful new trend?. Pediatrics 136 (2015), 1–3, 10.1542/peds.2015-0454.
34. Stogner, J.M., Miller, B.L., The dabbing dilemma: a call for research on butane hash oil and other alternate forms of cannabis use. Subst. Abuse 36 (2015), 393–395, 10.1080/08897077.2015.1071724.
35. Sullivan, N., Elzinga, S., Raber, J.C., 2013: Determination of pesticide residues in cannabis smoke. J. Toxicol., 2013, 378168, 10.1155/2013/378168.
36. Swift, W., Wong, A., Li, K.M., Arnold, J.C., McGregor, I.S., Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One, 8, 2013, e70052.
37. Troutt, W.D., DiDonato, M.D., Carbonyl compounds produced by vaporizing cannabis oil thinning agents. J. Altern. Complement. Med., 2017, 10.1089/acm.2016.0337.
38. UN Office on Drugs and Crime, World Drug Report 2015 (Vol. E. 15. XI.6)., 2015, UN Office on Drugs and Crime, United Nations New York, NY.
39. Winstock, A., Mitcheson, L.R., Deluca, P., Davey, Z., Corazza, O., Schifano, F., Mephedrone, new kid for the chop?. Addiction 106 (2011), 154–161, 10.1111/j.1360-0443.2010.03130.x.
40. Winstock, A., Lynskey, M., Borschmann, R., Waldron, J., Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J. Psychopharmacol. (Oxford, Engl.) 29 (2015), 698–703, 10.1177/0269881115574493.
41. van der Pol, P., Liebregts, N., de Graaf, R., Korf, D.J., van den Brink, W., van Laar, M., Validation of self-reported cannabis dose and potency: an ecological study. Addiction 108 (2013), 1801–1808, 10.1111/add.12226.